Abstract 3710
Background
In the ALTER0203 trial (NCT02449343), anlotinib hydrochloride was used as subsequence therapy for adult advanced soft tissue sacorma (STS) pts who progressed after prior systemic therapies. It has demonstrated that anlotinib significantly prolonged PFS in advanced STS with multiple pathological subgroups. There’s rare treatment method for alveolar soft part sarcoma (ASPS) due to chemotherapy insensitive. Here we report the efficacy of anlotinib on ASPS in 1st line or ≥ 2nd line.
Methods
233 pts were randomised in a 2:1 ratio to receive anlotinib (12 mg QD from day 1 to 14 of a 21-day cycle) or placebo till progression or intolerable toxicity. ASPS pts could be treated at 1st line without prior systemic therapies. Primary endpoint is progression-free survival (PFS). Data cutoff by 2017.4.30, follow-up is still ongoing.
Results
Median PFS of ASPS (n = 56) was significantly improved in the anlotinib arm (n = 38) compared with placebo arm (n = 18) (18.23 vs. 3.00 months, p < 0.0001), and the most common grade ≥3 treatment-related AEs were hypertension, γ-glutamyltransferase increased, hand-foot syndrome and hypertriglyceridemia. Furthermore, remarkable advantages in PFS were observed in the anlotinib arm as well regardless of the treatment line. Meanwhile, the DCR in anlotinib arm was also significantly increased compared to the placebo arm. (Data presented in the table)Table:
1694P Efficacy (date is immature)
1st line | ≥2nd line | |||||||
---|---|---|---|---|---|---|---|---|
Anlotinib (n = 18) | Placebo (n = 10) | HR | p-vaule | Anlotinib (n = 20) | Placebo (n = 8) | HR | P-vaule | |
Events/ Censored (n/n) | 6/12 | 5/5 | 5/15 | 6/2 | ||||
mPFS (mos) | 15.4 | 3.00 | 0.24 | 0.0073 | NR | 1.50 | 0.14 | <0.0001 |
ORR(%) | 22.22 | 0.00 | 0.2652 | 25.00 | 0.00 | 0.2808 | ||
DCR(%) | 83.33 | 40.00 | 0.0346 | 90.00 | 37.50 | 0.0095 |
Conclusions
In the ALTER0203 trial, a significant improvement in PFS was found in anlotinib treated ASPS from both subgroups (1st line or ≥ 2nd line treatment). This is indicating that anlotinib could be an appropriate option for ASPS pts regardless of the treatment line.
Clinical trial identification
NCT02449343.
Editorial acknowledgement
Legal entity responsible for the study
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Funding
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5314 - Spirituality and religious coping for Cancer patients and providers: An ‘Almighty’ belief for palliative care
Presenter: Vibhay Pareek
Session: Poster Display session 1
Resources:
Abstract
5519 - Is there a difference of Palliative care problems and needs between cancer and non-cancer hospitalized elderly patients?
Presenter: Ioanna Chatzi
Session: Poster Display session 1
Resources:
Abstract
2505 - There is a lack of clinical research for patients with cancer in palliative care
Presenter: Marie Vinches
Session: Poster Display session 1
Resources:
Abstract
5273 - Specialist Palliative Care (SPC) in Haematological Malignancy: Establishing practices in a UK Tertiary Cancer Centre (TCC)
Presenter: Emma Kedgley
Session: Poster Display session 1
Resources:
Abstract
5864 - Evaluation of the relationship between the attachment styles and psychological resilience of cancer patients receiving chemotherapy
Presenter: Fatma Bugdayci Basal
Session: Poster Display session 1
Resources:
Abstract
770 - Gefitinib along with Methotrexate as palliative therapy in PS 3 and above in metastatic squamous cell carcinoma head and neck cancer patients
Presenter: Vidya Dusi
Session: Poster Display session 1
Resources:
Abstract
4232 - High intensity end-of-life care in pediatrics, adolescent and young adult patients with cancer using an administrative database.
Presenter: Seiko Bun
Session: Poster Display session 1
Resources:
Abstract
4845 - Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital
Presenter: Deniz Can Guven
Session: Poster Display session 1
Resources:
Abstract
3270 - Internet-based stepped care for individuals with cancer and concurrent anxiety or depression symptoms – results from a randomized controlled trial
Presenter: Birgitta Johansson
Session: Poster Display session 1
Resources:
Abstract
5503 - Impact of Cognitive-Behavioral-Therapy (CBT) on levels of anxiety, depression and distress in cancer patients (pts)
Presenter: Daniela Tregnago
Session: Poster Display session 1
Resources:
Abstract